Literature DB >> 26512092

Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site.

Scott A Smith1, Usha K Nivarthi2, Ruklanthi de Alwis2, Nurgun Kose3, Gopal Sapparapu4, Robin Bombardi3, Kristen M Kahle5, Jennifer M Pfaff5, Sherri Lieberman5, Benjamin J Doranz5, Aravinda M de Silva6, James E Crowe7.   

Abstract

UNLABELLED: The proposed antibody-dependent enhancement (ADE) mechanism for severe dengue virus (DENV) disease suggests that non-neutralizing serotype cross-reactive antibodies generated during a primary infection facilitate entry into Fc receptor bearing cells during secondary infection, resulting in enhanced viral replication and severe disease. One group of cross-reactive antibodies that contributes considerably to this serum profile target the premembrane (prM) protein. We report here the isolation of a large panel of naturally occurring human monoclonal antibodies (MAbs) obtained from subjects following primary DENV serotype 1, 2, or 3 or secondary natural DENV infections or following primary DENV serotype 1 live attenuated virus vaccination to determine the antigenic landscape on the prM protein that is recognized by human antibodies. We isolated 25 prM-reactive human MAbs, encoded by diverse antibody-variable genes. Competition-binding studies revealed that all of the antibodies bound to a single major antigenic site on prM. Alanine scanning-based shotgun mutagenesis epitope mapping studies revealed diverse patterns of fine specificity of various clones, suggesting that different antibodies use varied binding poses to recognize several overlapping epitopes within the immunodominant site. Several of the antibodies interacted with epitopes on both prM and E protein residues. Despite the diverse genetic origins of the antibodies and differences in the fine specificity of their epitopes, each of these prM-reactive antibodies was capable of enhancing the DENV infection of Fc receptor-bearing cells. IMPORTANCE: Antibodies may play a critical role in the pathogenesis of enhanced DENV infection and disease during secondary infections. A substantial proportion of enhancing antibodies generated in response to natural dengue infection are directed toward the prM protein. The fine specificity of human prM antibodies is not understood. Here, we isolated a panel of dengue prM-specific human monoclonal antibodies from individuals after infection in order to define the mode of molecular recognition by enhancing antibodies. We found that only a single antibody molecule can be bound to each prM protein at any given time. Distinct overlapping epitopes were mapped, but all of the epitopes lie within a single major antigenic site, suggesting that this antigenic domain forms an immunodominant region of the protein. Neutralization and antibody-dependent enhanced replication experiments showed that recognition of any of the epitopes within the major antigenic site on prM was sufficient to cause enhanced infection of target cells.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26512092      PMCID: PMC4702676          DOI: 10.1128/JVI.01805-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Maturation of flaviviruses starts from one or more icosahedrally independent nucleation centres.

Authors:  Pavel Plevka; Anthony J Battisti; Jiraphan Junjhon; Dennis C Winkler; Heather A Holdaway; Poonsook Keelapang; Nopporn Sittisombut; Richard J Kuhn; Alasdair C Steven; Michael G Rossmann
Journal:  EMBO Rep       Date:  2011-05-13       Impact factor: 8.807

2.  The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity.

Authors:  Martina Beltramello; Katherine L Williams; Cameron P Simmons; Annalisa Macagno; Luca Simonelli; Nguyen Than Ha Quyen; Soila Sukupolvi-Petty; Erika Navarro-Sanchez; Paul R Young; Aravinda M de Silva; Félix A Rey; Luca Varani; Stephen S Whitehead; Michael S Diamond; Eva Harris; Antonio Lanzavecchia; Federica Sallusto
Journal:  Cell Host Microbe       Date:  2010-09-16       Impact factor: 21.023

3.  Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease.

Authors:  Raphaël M Zellweger; Tyler R Prestwood; Sujan Shresta
Journal:  Cell Host Microbe       Date:  2010-02-18       Impact factor: 21.023

4.  Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection.

Authors:  Scott A Smith; Yang Zhou; Nicholas P Olivarez; Anne H Broadwater; Aravinda M de Silva; James E Crowe
Journal:  J Virol       Date:  2011-12-14       Impact factor: 5.103

5.  Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification.

Authors:  Scott J Balsitis; Katherine L Williams; Ruben Lachica; Diana Flores; Jennifer L Kyle; Erin Mehlhop; Syd Johnson; Michael S Diamond; P Robert Beatty; Eva Harris
Journal:  PLoS Pathog       Date:  2010-02-12       Impact factor: 6.823

6.  Antibody recognition of a highly conserved influenza virus epitope.

Authors:  Damian C Ekiert; Gira Bhabha; Marc-André Elsliger; Robert H E Friesen; Mandy Jongeneelen; Mark Throsby; Jaap Goudsmit; Ian A Wilson
Journal:  Science       Date:  2009-02-26       Impact factor: 47.728

7.  Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Authors:  Laura M Walker; Sanjay K Phogat; Po-Ying Chan-Hui; Denise Wagner; Pham Phung; Julie L Goss; Terri Wrin; Melissa D Simek; Steven Fling; Jennifer L Mitcham; Jennifer K Lehrman; Frances H Priddy; Ole A Olsen; Steven M Frey; Phillip W Hammond; Stephen Kaminsky; Timothy Zamb; Matthew Moyle; Wayne C Koff; Pascal Poignard; Dennis R Burton
Journal:  Science       Date:  2009-09-03       Impact factor: 47.728

8.  Cross-reacting antibodies enhance dengue virus infection in humans.

Authors:  Wanwisa Dejnirattisai; Amonrat Jumnainsong; Naruthai Onsirisakul; Patricia Fitton; Sirijitt Vasanawathana; Wannee Limpitikul; Chunya Puttikhunt; Carolyn Edwards; Thaneeya Duangchinda; Sunpetchuda Supasa; Kriangkrai Chawansuntati; Prida Malasit; Juthathip Mongkolsapaya; Gavin Screaton
Journal:  Science       Date:  2010-05-07       Impact factor: 47.728

9.  A human PrM antibody that recognizes a novel cryptic epitope on dengue E glycoprotein.

Authors:  Annie Hoi Yi Chan; Hwee Cheng Tan; Angelia Yee Chow; Angeline Pei Chiew Lim; Shee Mei Lok; Nicole J Moreland; Subhash G Vasudevan; Paul A MacAry; Eng Eong Ooi; Brendon J Hanson
Journal:  PLoS One       Date:  2012-04-03       Impact factor: 3.240

10.  The global distribution and burden of dengue.

Authors:  Samir Bhatt; Peter W Gething; Oliver J Brady; Jane P Messina; Andrew W Farlow; Catherine L Moyes; John M Drake; John S Brownstein; Anne G Hoen; Osman Sankoh; Monica F Myers; Dylan B George; Thomas Jaenisch; G R William Wint; Cameron P Simmons; Thomas W Scott; Jeremy J Farrar; Simon I Hay
Journal:  Nature       Date:  2013-04-07       Impact factor: 49.962

View more
  26 in total

1.  Mechanism of Enhanced Immature Dengue Virus Attachment to Endosomal Membrane Induced by prM Antibody.

Authors:  Melissa Wirawan; Guntur Fibriansah; Jan K Marzinek; Xin Xiang Lim; Thiam-Seng Ng; Adelene Y L Sim; Qian Zhang; Victor A Kostyuchenko; Jian Shi; Scott A Smith; Chandra S Verma; Ganesh Anand; James E Crowe; Peter J Bond; Shee-Mei Lok
Journal:  Structure       Date:  2018-11-21       Impact factor: 5.006

Review 2.  The Antigenic Structure of Zika Virus and Its Relation to Other Flaviviruses: Implications for Infection and Immunoprophylaxis.

Authors:  Franz X Heinz; Karin Stiasny
Journal:  Microbiol Mol Biol Rev       Date:  2017-02-08       Impact factor: 11.056

3.  Cross-reactive antibodies facilitate innate sensing of dengue and Zika viruses.

Authors:  Laura K Aisenberg; Kimberly E Rousseau; Katherine Cascino; Guido Massaccesi; William H Aisenberg; Wensheng Luo; Kar Muthumani; David B Weiner; Stephen S Whitehead; Michael A Chattergoon; Anna P Durbin; Andrea L Cox
Journal:  JCI Insight       Date:  2022-06-22

4.  Resurfaced ZIKV EDIII nanoparticle immunogens elicit neutralizing and protective responses in vivo.

Authors:  George I Georgiev; Ryan J Malonis; Ariel S Wirchnianski; Alex W Wessel; Helen S Jung; Sean M Cahill; Elisabeth K Nyakatura; Olivia Vergnolle; Kimberly A Dowd; David Cowburn; Theodore C Pierson; Michael S Diamond; Jonathan R Lai
Journal:  Cell Chem Biol       Date:  2022-02-28       Impact factor: 9.039

5.  Protective Zika vaccines engineered to eliminate enhancement of dengue infection via immunodominance switch.

Authors:  Lianpan Dai; Kun Xu; Jinhe Li; Qingrui Huang; Jian Song; Yuxuan Han; Tianyi Zheng; Ping Gao; Xuancheng Lu; Huabing Yang; Kefang Liu; Qianfeng Xia; Qihui Wang; Yan Chai; Jianxun Qi; Jinghua Yan; George F Gao
Journal:  Nat Immunol       Date:  2021-07-15       Impact factor: 25.606

6.  Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine.

Authors:  Wen-Yang Tsai; Hui-Ling Chen; Jih-Jin Tsai; Wanwisa Dejnirattisai; Amonrat Jumnainsong; Juthathip Mongkolsapaya; Gavin Screaton; James E Crowe; Wei-Kung Wang
Journal:  J Virol       Date:  2018-11-12       Impact factor: 5.103

7.  Isolation of a Potently Neutralizing and Protective Human Monoclonal Antibody Targeting Yellow Fever Virus.

Authors:  Michael P Doyle; Joseph R Genualdi; Adam L Bailey; Nurgun Kose; Christopher Gainza; Jessica Rodriguez; Kristen M Reeder; Christopher A Nelson; Prashant N Jethva; Rachel E Sutton; Robin G Bombardi; Michael L Gross; Justin G Julander; Daved H Fremont; Michael S Diamond; James E Crowe
Journal:  mBio       Date:  2022-04-14       Impact factor: 7.786

Review 8.  The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design.

Authors:  Félix A Rey; Karin Stiasny; Marie-Christine Vaney; Mariano Dellarole; Franz X Heinz
Journal:  EMBO Rep       Date:  2017-12-27       Impact factor: 8.807

9.  Pichia pastoris-Expressed Bivalent Virus-Like Particulate Vaccine Induces Domain III-Focused Bivalent Neutralizing Antibodies without Antibody-Dependent Enhancement in Vivo.

Authors:  Rahul Shukla; Ravi K Rajpoot; Upasana Arora; Ankur Poddar; Sathyamangalam Swaminathan; Navin Khanna
Journal:  Front Microbiol       Date:  2018-01-09       Impact factor: 5.640

10.  Identification of Anti-Premembrane Antibody as a Serocomplex-Specific Marker To Discriminate Zika, Dengue, and West Nile Virus Infections.

Authors:  Szu-Chia Hsieh; Wen-Yang Tsai; Jih-Jin Tsai; Mars Stone; Graham Simmons; Michael P Busch; Marion Lanteri; Susan L Stramer; Angel Balmaseda; Eva Harris; Wei-Kung Wang
Journal:  J Virol       Date:  2021-09-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.